Concentrix reported adjusted earnings per share of $2.95 for the fourth quarter of fiscal 2025, surpassing analyst forecasts of $2.93. Revenue for the period reached $2.55 billion, topping consensus estimates of $2.54 billion and marking a 5% year-over-year increase on a constant currency basis. Management attributed the revenue growth to strong demand for digital customer engagement solutions in the healthcare and high-tech verticals, which together accounted for over 40% of total sales.

Operating cash flow for fiscal 2025 set a new company record at $807 million, while adjusted free cash flow totaled $626 million, reflecting a 12% improvement over the prior year. These cash metrics underscore Concentrix’s ability to convert sales into liquidity. In the fourth quarter, the company recognized a non-cash goodwill impairment charge of $1.5 billion related to its Europe-based operations, primarily driven by shifts in client project timelines. Despite this one-time charge, management reiterated its target to deliver mid-single-digit free cash flow conversion in fiscal 2026.

During fiscal 2025, Concentrix returned $258 million to shareholders through share repurchases and dividends, representing approximately 8% of free cash flow. The company ended the year with a debt-to-equity ratio of 1.11 and a current ratio of 1.56, indicating a balanced capital structure and ample liquidity to cover short-term obligations. Valuation metrics remain attractive, with a price-to-earnings ratio of 7.83 and a price-to-sales ratio of 0.26. Enterprise value to sales and operating cash flow multiples stood at 0.72 and 9.32 respectively, while the earnings yield reached 12.77%, underscoring potential upside for long-term investors.